Tolcapone
Brand: Tasmar (US/EU) / Tolcap (IN) / Tolcom (BD)
Antiparkinson
COMT inhibitor
Pharmacokinetics
| Half-life | 2 hours |
| Tmax | 2 h |
| Bioavailability | 60 % (approx) |
| Protein Binding | 98 % |
| Volume of Distribution | 0.3 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | Severe hepatotoxicity risk; not preferred over entacapone unless carefully monitored. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Severe hepatotoxicity, diarrhea, dyskinesias, nausea
Contraindications:
Active liver disease or hepatic impairment
Precautions:
Frequent liver function tests mandatory; discontinue if LFTs increase